ArticleInfection and immunity2005
Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 99 citations in OpenAlex.
- Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.The New England journal of medicine · 2024Article
- The Use of Viral Vectors for Gene Therapy and Vaccination in Tuberculosis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pseudomonas Aeruginosa Lung Infection Subverts Lymphocytic Responses through IL-23 and IL-22 Post-Transcriptional Regulation.International journal of molecular sciences · 2022Article
- Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?Frontiers in immunology · 2021Review
- Monocytic-Myeloid Derived Suppressor Cells of HIV-Infected Individuals With Viral Suppression Exhibit Suppressed Innate Immunity toFrontiers in immunology · 2021Article
- Advancing Adjuvants forFrontiers in immunology · 2021Review
- Therapeutic host-directed strategies to improve outcome in tuberculosis.Mucosal immunology · 2020Review
- Tools for Assessing the Protective Efficacy of TB Vaccines in Humans:Frontiers in immunology · 2019Article
- Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a commonScience immunology · 2018Article
- Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23.Science immunology · 2018Article
- The increased protection and pathology in Mycobacterium tuberculosis-infected IL-27R-alpha-deficient mice is supported by IL-17A and is associated with the IL-17A-induced expansion of multifunctional T cells.Mucosal immunology · 2018Article
- Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis.The Journal of pathology · 2018Article
- Cytokines and Chemokines in Mycobacterium tuberculosis Infection.Microbiology spectrum · 2016Review
- Fasciola hepatica infection reduces Mycobacterium bovis burden and mycobacterial uptake and suppresses the pro-inflammatory response.Parasite immunology · 2016Article
- The Role of Neutrophils in the Induction of Specific Th1 and Th17 during Vaccination against Tuberculosis.Frontiers in microbiology · 2016Article
- Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection.Immunology · 2013Article
- Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis.Mucosal immunology · 2013Article
- Human phagosome processing of Mycobacterium tuberculosis antigens is modulated by interferon-γ and interleukin-10.Immunology · 2013Article
- Article
- IL23R(Arg381Gln) functional polymorphism is associated with active pulmonary tuberculosis severity.Clinical and vaccine immunology : CVI · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of IL-23 on the outcome of pulmonary infection with M. tuberculosis have not been described. Here, we show that local delivery of replication-defective adenovirus vectors encoding IL-23 (AdIL-23) greatly stimulated expression of both gamma interferon (IFN-gamma) and IL-17 in lung tissues of otherwise normal mice. When given 72 h prior to infection with M. tuberculosis, AdIL-23 significantly reduced the bacterial burden at 14, 21, and 28 days. Markedly lower levels of lung inflammation were observed at 28 days than in control mice pretreated with control adenovirus (AdNull) or vehicle controls. AdIL-23 pretreatment resulted in increased numbers of CD4(+) CD25(+) activated T cells in lungs and draining lymph nodes compared to control groups and more CD4(+) T cells bearing surface memory markers in lung lymph nodes. IL-23 gene delivery also significantly enhanced host anti-mycobacterial T-cell responses, as shown by elevated levels of IFN-gamma and IL-17 secreted in vitro following restimulation with M. tuberculosis purified protein derivative. Overall, our data show that transient IL-23 gene delivery in the lung is well tolerated, and they provide the initial demonstration that this factor controls mycobacterial growth while augmenting early pulmonary T-cell immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.